NovaBridge Biosciences (FRA:0VY) Total Liabilities: €25.26 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:0VY NovaBridge Biosciences FRA:0VY
32 GF Score
Price €1.53
! 2 Warning Signs
View Full Analysis

What is NovaBridge Biosciences Total Liabilities?

NovaBridge Biosciences FRA:0VY -3.16% 32 Total Liabilities is €25.26 Mil as of Dec. 2025. GuruFocus rates FRA:0VY with a GF Score™ of 32/100. The stock has 2 warning signs investors should review.

NovaBridge Biosciences's Total Liabilities for the quarter that ended in Dec. 2025 was €25.26 Mil.

NovaBridge Biosciences's quarterly Total Liabilities increased from Jun. 2025 (€8.65 Mil) to Sep. 2025 (€15.76 Mil) and increased from Sep. 2025 (€15.76 Mil) to Dec. 2025 (€25.26 Mil).

NovaBridge Biosciences's annual Total Liabilities declined from Dec. 2023 (€115.85 Mil) to Dec. 2024 (€11.00 Mil) but then increased from Dec. 2024 (€11.00 Mil) to Dec. 2025 (€25.26 Mil).

NovaBridge Biosciences Total Liabilities Historical Data

* Premium members only.

The historical data trend for NovaBridge Biosciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NovaBridge Biosciences Total Liabilities Chart

NovaBridge Biosciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only 144.62 159.23 115.85 11.00 25.26

NovaBridge Biosciences Quarterly Data
Sep19 Dec19 Jun20 Sep20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.00 9.81 8.65 15.76 25.26
FRA:0VY
32GF Score
NovaBridge Biosciences FRA:0VY
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NovaBridge Biosciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

NovaBridge Biosciences's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=22.967+(1.858+0.437
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=25.26

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=222.486-197.224
=25.26

NovaBridge Biosciences's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=22.967+(1.858+0.437
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=25.26

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=222.486-197.224
=25.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €25.26 Mil mean?
NovaBridge Biosciences (FRA:0VY) has a Total Liabilities of €25.26 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for NovaBridge Biosciences and its competitors.
Is NovaBridge Biosciences' Total Liabilities too high?
NovaBridge Biosciences' current Total Liabilities is €25.26 Mil. Overall, NovaBridge Biosciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does NovaBridge Biosciences' Total Liabilities compare to HUMA and DTIL?
NovaBridge Biosciences' Total Liabilities of €25.26 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for NovaBridge Biosciences and its competitors. NovaBridge Biosciences's current Total Liabilities is €25.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovaBridge Biosciences stock overvalued right now?
NovaBridge Biosciences (FRA:0VY) has a current Total Liabilities of €25.26 Mil. The current Total Liabilities is €25.26 Mil. NovaBridge Biosciences' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For NovaBridge Biosciences (FRA:0VY), the current Total Liabilities is €25.26 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NovaBridge Biosciences Business Description

Other Exchanges NBP:USA
Address 2440 Research Boulevard, Suite 400, Rockville, MD, USA, 20850
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
32GF Score

Get the complete analysis for FRA:0VY

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.53
Price